London stocks had extended gains by midday on Friday as Chinese markets enjoyed their best week since 2008 on the back of ...

Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Jeffrey Rubin, the president and director of research at Westport, Conn.-based Birinyi Associates - who now owns the firm following the death of the legendary Laszlo Birinyi - is among those who is ...

FRIDAY, Sept. 27, 2024 (HealthDay News) -- The first new type of medication in decades to help fight against schizophrenia ...

Fidelity slashed the amount certain customers can deposit into their cash-management accounts to $1,000 from $100,000, people familiar with the matter said. The Boston firm is also subjecting some ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

A Commerce Department report, due at 8:30 a.m. ET, is expected to show the Personal Consumption Expenditure Index - the Fed's ...